An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain

Trial Profile

An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Cancer pain; Pain
  • Focus Adverse reactions
  • Sponsors Mallinckrodt Inc.
  • Most Recent Events

    • 02 Jun 2017 Planned End Date changed from 1 Oct 2016 to 1 Jan 2019.
    • 02 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2019.
    • 25 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top